#Keynote 189 plus#

METHODS Patients were randomly assigned (2:1) to receive pemetrexed and platinum plus pembrolizumab (n 410) or placebo (n 206) every 3 weeks for 4 cycles, then pemetrexed maintenance plus pembrolizumab or placebo for up to a total of 35 cycles.

Learn more about how Apple Card applications are evaluated at /kb/HT209218. We report an updated analysis from KEYNOTE-189 (: NCT02578680).

Apple Card is issued by Goldman Sachs Bank USA, Salt Lake City Branch.

There was 2:1 randomization of that same combination versus standard pemetrexed and carboplatin.

#Keynote 189 trial#

Available for qualifying applicants in the United States. KEYNOTE-189 was the follow-up randomized phase III trial. Merck announced results from KEYNOTE-189, a pivotal Phase 3 trial evaluating KEYTRUDA®, Merck’s anti-PD-1 therapy, in combination with pemetrexed and cisplatin or carboplatin for the first-line.

#Keynote 189 update#

Update to the latest version by going to Settings > General > Software Update.

To access and use all the features of Apple Card, you must add Apple Card to Wallet on an iPhone or iPad with the latest version of iOS or iPadOS. Clinical evidence for pembro+chemo is predominantly derived from Keynote-189, an ongoing, global phase-III, double-blind, active-controlled trial in.

To get the newest features, make sure your devices are running the latest software version.

Apple Fitness+ requires iOS 14.3 or later, iPadOS 14.3 or later, watchOS 7.2 or later, and tvOS 14.3 or later. Gadgeel, MD, MBBS, professor, University of Michigan Medicine, discusses the updated results of the phase III KEYNOTE-189 trial in metastatic nonsquamous non-small cell lung cancer (NSCLC).

A subscription is required for Apple Fitness+.

It cannot be sold or delivered until the FCC’s authorization process is complete. Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC).

iPhone 14 Plus is subject to FCC rules as well as consumer protection, contractual, and other provisions of federal or state law. PURPOSE: In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous nonsmall-cell lung cancer (NSCLC), irrespective of tumor programmed death-ligand 1 (PD-L1) expression.

For more information, visit /us-hed/shop.

Education pricing is available to current and newly accepted college students and their parents, as well as faculty, staff, and homeschool teachers of all grade levels. Plan automatically renews until cancelled. At data cutoff, 7 patients had initiated second-course pembrolizumab. 45 patients (80.4%) were alive at data cutoff (28 without PD), and 2-year OS after completion of 35 cycles was 79.6%. Final analysis of KEYNOTE-189: pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated. Among 56 patients who completed 35 cycles (2 years) of pembrolizumab, 49 (87.5%) had an objective response (CR, n=6 PR, n=43) and 7 (12.5%) had SD. Grade 3‒5 AEs occurred in 72.1% patients in the pembrolizumab plus pemetrexed-platinum group and 67.3% patients in the placebo plus pemetrexed-platinum group. Patients (616) were randomized, 2:1, to receive pemetrexed and a platinum-based chemotherapy plus either pembrolizumab (test arm) or placebo (control arm). Median (95% CI) PFS was 9.0 (8.1‒10.4) months vs 4.9 (4.7‒5.5) months, respectively (HR, 0.50 95% CI, 0.41‒0.59). KEYNOTE-189 is a randomized, double-blind, phase III study in patients with metastatic nonsquamous NSCLC who received no prior treatment for metastatic disease.

Median (95% CI) OS was 22.0 (19.5‒24.5) months with pembrolizumab plus pemetrexed-platinum vs 10.6 (8.7‒13.6) months with placebo plus pemetrexed-platinum (hazard ratio, 0.60 95% CI, 0.50‒0.72). Efficacy outcomes are summarized in the Table. 84 patients (40.8%) randomized to the control group crossed over to pembrolizumab monotherapy on-study. Median (range) time from randomization to data cutoff (August 28, 2020) was 46.3 (41.8–54.1) months.

616 patients were randomized (pembrolizumab plus pemetrexed-platinum, n=410 placebo plus pemetrexed-platinum, n=206).